title: Plasma carnitine in HIV-associated neuropathy.
authors.forename: D M
authors.initials: DM
authors.lastname: Simpson
authors.forename: D
authors.initials: D
authors.lastname: Katzenstein
authors.forename: B
authors.initials: B
authors.lastname: Haidich
authors.forename: D
authors.initials: D
authors.lastname: Millington
authors.forename: C
authors.initials: C
authors.lastname: Yiannoutsos
authors.forename: G
authors.initials: G
authors.lastname: Schifitto
authors.forename: J
authors.initials: J
authors.lastname: McArthur
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects; D002331:Carnitine / Q000097:blood*; D015224:Dideoxynucleosides / Q000009:adverse effects; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D020932:Nerve Growth Factor / Q000235:genetics / Q000627:therapeutic use*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000188:drug therapy*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects
chemical_list: D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D018894:Reverse Transcriptase Inhibitors; D020932:Nerve Growth Factor; D002331:Carnitine